Table 2.

Baseline Characteristics of Patients and the Clinical Background of the Third-generation and Non-third-generation Cephalosporin Treatment Groups after Propensity Score Matching.

Variable	Third-generation cephalosporins (n=53)		Non-third-generation cephalosporins (n=53)		p value
Age, ≥65 years; n (%)	42	(79.2)	37	(69.8)	0.373a
Sex, Male (%)	36	(67.9)	38	(71.7)	0.833a
Charlson Comorbidity Index; median (IQR)	3.0	(2.0-4.0)	3.0	(2.0-5.0)	0.369b
Disseminated intravascular coagulation; n (%)	6	(11.3)	7	(13.2)	1.000a
Anticancer agents or immunosuppressants; n (%)	24	(45.3)	21	(39.6)	0.695a
Source of Infection
Lower gastrointestinal tract or intra-abdominal; n (%)	3	(5.7)	4	(7.5)	1.000a
Biliary tract; n (%)	21	(39.6)	22	(41.5)	1.000a
Urinary tract; n (%)	13	(24.5)	14	(26.4)	1.000a
Respiratory system; n (%)	3	(5.7)	0	(0)	0.243a
Intravenous catheter; n (%)	2	(3.8)	0	(0)	0.495a
Unclear or others; n (%)	11	(20.8)	13	(24.5)	0.817a
Clinical characteristics
eGFR, mL/min/1.73 m2; median (IQR)	55.0	(36.0-70.0)	59.0	(42.3-73.7)	0.774b
WBC, /μL; median (IQR)	7,600	(4,300-9,800)	8,500	(4,700-11,500)	0.822b
CRP (≥15), mg/dL; n (%)	5	(9.4)	6	(11.3)	1.000a
Pitt Bacteremia Score (≥4 points); n (%)	16	(30.2)	19	(35.8)	0.680a
Implementation of source control; n (%)	21	(39.6)	22	(41.5)	1.000a
Duration of antimicrobial administration, days; median (IQR)	13.0	(9.0-16.0)	13.0	(9.0-15.0)	0.869b
Microorganisms
Enter obacter cloacae or Enterobacter cloacae complex; n (%)	36	(67.9)	34	(64.2)	0.838a
Klebsiella aero genes; n (%)	14	(26.4)	16	(30.2)	0.830a
Other Enterobacter spp.; n (%)	3	(5.7)	3	(5.7)	1.000a

^aFisher’s exact test, ^bMann-Whitney U test. IQR: interquartile range, eGFR: estimated glomerular filtration rate, WBC: white blood cell, CRP: C-reactive protein